Journal
PHARMACOTHERAPY
Volume 35, Issue 9, Pages 823-837Publisher
WILEY
DOI: 10.1002/phar.1629
Keywords
heart failure with reduced ejection fraction; systolic heart failure; neprilysin inhibition; therapeutic review; pharmacotherapy
Categories
Ask authors/readers for more resources
There has been a 10-year hiatus in the approval of a new pharmacotherapy for patients with chronic heart failure with a reduced ejection fraction (HFrEF). Combining an angiotensin receptor blocker, valsartan, with sacubitril, an inhibitor of neprilysin, results in increasing levels of natriuretic peptides that counterbalance high circulating levels of neurohormones in HFrEF. This has resulted in the development of a new agent, LCZ696. A comprehensive overview of LCZ696, its pharmacology, its role in the pathophysiology of HFrEF, completed and future clinical trial information, specific critical issues, and the place of LCZ696 in HFrEF therapy are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available